Development of epitope‐based peptide vaccine against novel coronavirus 2019 (SARS‐COV‐2): Immunoinformatics approach

Bhattacharya, Manojit; Sharma, Ashish Ranjan; Patra, Prasanta; Ghosh, Pratik; Sharma, Garima; Patra, Bidhan Chandra; Lee, Sang-Soo; Chakraborty, Chiranjib

doi:10.1002/jmv.25736

Cited by 360 publications

(348 citation statements)

References 27 publications

Supporting

Mentioning

335

Contrasting

Unclassified

Order By: Relevance

“…To date, there is no specific cure for Covid-19, although clinical management of these patients currently includes prevention or control of the infection and supportive care, including supplemental oxygen and mechanical ventilation support when needed. Recently, in the viral surface glycoprotein, several epitopes, including in 5 CTL epitopes, 3 sequential B cell epitopes, 5 discontinuous B cell epitopes of immune cells [20], and 13 MHC-I and 3 MHC-II antigenic epitopes [21], have been reported via immuno-informatics approach that some of these epitopes maybe had potential candidates for the development of 2019-nCoV vaccines.…”

Section: Sars-cov-2 and Covid-19mentioning

confidence: 99%

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Golchin

Seyedjafari

Ardeshirylajimi

2020

Stem Cell Rev and Rep

304

302

View full text Add to dashboard Cite

" is the word that certainly isn't forgotten by everybody who lives in the first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. Recently, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in stem cell therapy. In this study, we considered this new approach to improve patient's immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. However, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing.

show abstract

Section: Sars-cov-2 and Covid-19mentioning

confidence: 99%

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Golchin

Seyedjafari

Ardeshirylajimi

2020

Stem Cell Rev and Rep

304

302

View full text Add to dashboard Cite

show abstract

“…However, it must be emphasized that the therapeutic potential of hydroxychloroquine is still controversial and begs for further investigation. Aside from repurposing existing therapies, there is an increasing demand for immunotherapy, driven by immunoinformatics and comparison homology sequencing with SARS-CoV to narrow down epitopes as potential candidates to design a peptide vaccine against SARS-CoV-2 (1,4,7,19). Another approach that has been proposed is to passively immunize newly infected patients with IgG antibodies collected from patients that have recovered from COVID-19 (24).…”

mentioning

confidence: 99%

Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease

Golonka

Saha

Yeoh

et al. 2020

Physiological Genomics

View full text Add to dashboard Cite

“…Here we have designed a multiepitope-based vaccine for the SARS-CoV-2 using next generation vaccinology approach where the recently available genome and proteome of the SARS-CoV-2 were maneuvered and a potential vaccine candidate was conceived. Similar strategy was employed previously for SARS-CoV and MERS-CoV [20][21][22][23][24][25] as well as certain findings are reported for the newly emerged SARS-CoV-2 [26][27][28]. While immunoinformatics techniques was utilized by groups to predict the B-cell and cytotoxic T-cell epitopes in the SARS-CoV-2 surface glycoprotein, N protein [27][28][29], others have utilized the information to design epitope-based vaccine based on the SARS-CoV-2 spike glycoprotein [26].…”

mentioning

confidence: 68%

Scrutinizing the SARS-CoV-2 protein information for the designing an effective vaccine encompassing both the T-cell and B-cell epitopes

Jain

Shankar

Majee

et al. 2020

Preprint

View full text Add to dashboard Cite

Novel SARS coronavirus (SARS-CoV-2) has caused a pandemic condition world-wide and has been declared as public health emergency of International concern by WHO in a very short span of time. The community transmission of this highly infectious virus has severely affected various parts of China, Italy, Spain and USA among others. The prophylactic solution against SARS-CoV-2 infection is challenging due to the high mutation rate of its RNA genome. Herein, we exploited a next generation vaccinology approach to construct a multi-epitope vaccine candidate against SARS-CoV-2 with high antigenicity, safety and efficacy to combat this deadly infectious agent. The whole proteome was scrutinized for the screening of highly conserved, antigenic, non-allergen and non-toxic epitopes having high population coverage that can elicit both humoral and cellular mediated immune response against COVID-19 infection. These epitopes along with four different adjuvants were utilized to construct a multi-epitope vaccine candidate that can generate strong immunological memory response having high efficacy in humans. Various physiochemical analyses revealed the formation of a stable vaccine product having a high propensity to form a protective solution against the detrimental SARS-CoV-2 strain with high efficacy. The vaccine candidate interacted with immunological receptor TLR3 with high affinity depicting the generation of innate immunity. Further, the codon optimization and in silico expression show the plausibility of the high expression and easy purification of the vaccine product. Thus, this present study provides an initial platform of the rapid generation of an efficacious protective vaccine for combating COVID-19.

show abstract

Development of epitope‐based peptide vaccine against novel coronavirus 2019 (SARS‐COV‐2): Immunoinformatics approach

Cited by 360 publications

References 27 publications

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease

Scrutinizing the SARS-CoV-2 protein information for the designing an effective vaccine encompassing both the T-cell and B-cell epitopes

Contact Info

Product

Resources

About